The therapeutic landscape of multiple myeloma (MM) has benefited from an emergence of
novel therapies over the last decade. By inducing T-cell kill of target cancer cells, chimeric …

Anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapies
currently approved by the US Food and Drug Administration (FDA) have dramatically …

Background: First-line treatment of diffuse large B-cell lymphoma (DLBCL) achieves durable
remission in approximately 60% of patients. In relapsed or refractory disease, only about …

Chimeric antigen receptor (CAR) T-cell (CAR-T) therapies genetically modify a person's own
T cells to bind to antigens expressed on cancer cells. 1, 2 CAR-T has generated sizable …

Autologous chimeric antigen receptor T-cell (CAR-T) therapies targeting B-cell maturation
antigen (BCMA) have revolutionized the field of multiple myeloma in the same way that the …

Introduction Despite remarkable therapeutic advances over the last two decades, which
have resulted in dramatic improvements in patient survival, multiple myeloma (MM) is still …

Intent Matters: Real-World Applicability of Idecabtagene Vicleucel Usage in the United States
Intent Matters: Real-World Applicability of Idecabtagene Vicleucel Usage in the United States …

Chimeric Antigen Receptor T-cell (CAR-T) therapies are transforming the treatment of B-cell
lymphoproliferative disorders and multiple myeloma, yet global access challenges and …

The use of chimeric antigen receptro T-cell therapy all over (CAR-T)-cell therapy in multiple
myeloma (MM) showed early promising results in heavily pre-treated patient with limited …

The question of whether chimeric antigen receptor (CAR) T cell therapies should be used in
earlier lines (after 1–2 prior lines of therapy) in patients with relapsed and/or refractory …